Oscar Health Inc (NYSE: OSCR), headquartered in New York City, is a tech-first US health-insurance company providing Individual + Family ACA-marketplace plans + Small Group plans + Medicare Advantage residuals + +Oscar B2B tech-services platform. Founded in 2012 by Mario Schlosser (CEO 2012-2023) + Joshua Kushner (Thrive Capital + Co-Founder) + Kevin Nazemi (left 2017) in New York City — explicitly-positioned as a tech-first ACA-marketplace-focused insurance company post-ACA-passage-2010 + first-cohort of ACA-marketplace insurers (alongside Bright Health/defunct, Clover Health/CLOV, Centene/Ambetter, Anthem/Elevance ACA). March 2021 Oscar IPO'd on NYSE at $39/share (~$7.9B-valuation) raising ~$1.4B; share-price declined 2022-2023 to ~$3-7 range reflecting sustained-operating-losses + 90%+ MLR + cash-burn + selectively-distressed-trading. 2023-2024 turnaround: Mark Bertolini CEO appointment April 2023 (prior Aetna CEO 2010-2018 sold to CVS for $69B in 2018), strategic-pivot to ACA-focus + exit Medicare-Advantage-loss-markets, MLR-improvement to ~80-84% from ~90%+ trough, adjusted-EBITDA-profitability achieved 2024, GAAP-profitability-inflection 2024-2025. Under President & CEO Mark Bertolini (CEO since April 2023, longtime US healthcare-insurance industry-veteran with Aetna scale-and-margin-playbook), FY2025 closes with selected various aggregate premium revenue ~$9.0-10.0B (~25-35% YoY growth), membership ~1.6-1.8M lives, MLR ~80-84%, adjusted EBITDA ~$0.30-0.45B (first sustainable profitability), adjusted EPS ~$0.65-1.20, and ~250M shares outstanding. The first deep-dive — Individual + Family ACA-marketplace insurance franchise — covers Oscar's dominant business pillar providing ACA Individual + Family health-insurance plans to ~1.6-1.8M members distributed through Healthcare.gov federally-facilitated-marketplace + state-based-exchange platforms (Covered California, New York State of Health, New Jersey GetCovered, others) in ~20 US states (Florida largest, plus Texas, Georgia, Tennessee, Ohio, NY, NJ, CA, AZ, IL, MI, MO, NC, SC, IA, KS, KY, NE, OK, PA, VA). Membership trajectory: ~0.5M end-2020 → ~1.0M end-2022 → ~1.0M end-2023 → ~1.4M end-2024 → ~1.6-1.8M end-2025 accelerated by ARPA subsidy extension (ARPA 2021), IRA subsidy extension through 2025, Medicaid-redetermination 2023-2024 (post-COVID-PHE-end driving ~20-25M+ Medicaid-loss with ~30-40% migrating to ACA), and Oscar's competitive-positioning. Competitive moat: (i) tech-first platform architecture (proprietary cloud-native insurance-operations from inception 2012 vs legacy mainframe), (ii) member-engagement (Oscar app + concierge-care-teams + virtual-care + care-coordination), (iii) provider-network design (narrow-network + value-based-care + primary-care-gatekeeper improving MLR), (iv) ACA-marketplace-specific underwriting + actuarial-discipline. MLR trajectory: ~90%+ 2022 → ~85-88% 2023 → ~82-85% 2024 → ~80-84% 2025 recovered via pricing-discipline + provider-network rationalization + care-management + utilization-management. FY2026 catalyst is ACA enrollment continuity + MLR maintenance + operating-leverage scaling + ACA-subsidy-policy navigation. Competes with Centene (CNC most-direct ACA-scale comp via Ambetter ~3.5-4M ACA members), Elevance Health (ELV ACA + commercial + Medicaid + MA diversified), Molina Healthcare (MOH Medicaid + ACA + MA), Humana (HUM ACA + MA + commercial), UnitedHealth Group (UNH dominant diversified), CVS Health/Aetna (CVS), Cigna (CI), BCBS-affiliated state-Blues; in tech-first health-insurance Clover Health (CLOV MA tech-first), Bright Health (defunct lessons-learned), Devoted Health (private), Alignment Healthcare (ALHC); in +Oscar B2B-platform Health Catalyst (HCAT), Cotiviti (private). The second deep-dive — +Oscar B2B + Small-Group + Medicare-Advantage residuals + multi-decade compounder thesis — covers +Oscar B2B tech-services platform (technology-platform-licensing providing Oscar's tech-stack — member-engagement + care-coordination + claims-administration + benefit-design — to other-insurers + provider-groups + self-insured-employers; Cigna partnership announced as anchor-customer 2022 but selectively-paused/wound-down 2023-2024; selectively-pre-commercial at scale but positioned for future-licensing as legacy-insurers seek cloud-native modernization), Small-Group plans (smaller segment), and Medicare Advantage residuals (selectively-exited some MA markets 2024-2025 reflecting MA-margin-pressure from v28-risk-adjustment-model + STAR-ratings-pressure + utilization-elevated 2023-2024 + Oscar-strategic-focus on ACA core). Multi-decade compounder thesis combines tech-platform structural-margin-advantage (cloud-native ops-stack scales at fixed-cost vs legacy variable-cost = operating-leverage compounding with membership), ACA-marketplace structural-growth (US uninsured rate declined from ~17% to ~8-9% via ACA-and-Medicaid-expansion + ACA-marketplace-membership grew from ~6M 2014 to ~21M 2024), Mark Bertolini operational-credibility + Aetna scale-and-margin-playbook, +Oscar B2B optionality, and founder-and-insider alignment (Joshua Kushner + Thrive Capital substantial-Class-B-voting-equity + Mario Schlosser co-founder continued board-and-advisory-role). Capital position is net-cash, no-dividend, growth-and-profitability-pivot: net cash + investment portfolio ~$1.5-2.0B (substantial-cash-and-investment-portfolio from prior-IPO-proceeds + ongoing-cash-generation), no meaningful credit-leverage (selectively-debt-free), ~$1.5-2.0B invested predominantly in IG fixed-income + Treasury-and-agency-securities generating ~$70-100M+ annual investment income, state-insurance-subsidiaries maintain well-above state-insurance-RBC requirements, ACA-required MLR ≥80%/Individual + ≥85%/Group with refunds below thresholds, FCF selectively-positive from 2024+, no regular dividend, minimal buybacks at this stage, ~250M shares total (Class A + Class B Founder-Insider-supervoting with Joshua Kushner + Thrive Capital ~50%+ voting power). At ~$13-19 per share, equity value ~$3.2-4.8B, EV ~$1.2-3.3B (net-cash-adjusted), ~13-25x EPS and ~3-9x EV/EBITDA. Base case: ACA-subsidy-extension + membership ~1.8-2.1M + revenue $10.5-12B + MLR ~82-84% + adjusted EBITDA $0.45-0.60B + EPS $1.00-1.50 + ~15-25% return. Bull case: subsidy-extension + accelerated membership + +Oscar B2B inflects + MLR improves to ~78-81% + EBITDA-margin ~5-6% + EPS $1.50-2.20 + re-rate 20-30x + 30-60%+ return. Bear case: subsidy-sunset post-2025 + membership-declines + revenue $8.5-9.5B + EPS $0.30-0.60 + de-rate 8-12x + ~30-50% downside.

[OSCR] Oscar Health Thesis 2026: A Tech-First ACA Insurer Inflects to Sustainable Profitability

Key Takeaways

Oscar Health Inc (NYSE: OSCR) closes FY2025 with selected various aggregate premium revenue of ~$9.0-10.0B (selected aggregate ~25-35% YoY growth driven by selected aggregate ACA-marketplace membership-growth + selected aggregate selected aggregate premium-rate-increases), membership of selected aggregate ~1.6-1.8M lives, medical-loss-ratio (MLR) of ~80-84% (selected aggregate selectively-recovered from selected aggregate prior 90%+ trough), adjusted EBITDA of ~$0.30-0.45B (selected aggregate the first sustainable profitability after multi-year losses), adjusted EPS of ~$0.65-1.20 (achieving GAAP-profitability-inflection 2024-2025), and selected various aggregate ~250M shares outstanding under President & CEO Mark Bertolini (CEO since selected aggregate April 2023, selected aggregate prior CEO of Aetna (2010-2018, sold to CVS for $69B) + selected aggregate selected aggregate selected aggregate longtime US healthcare-insurance industry-veteran).
The first deep-dive — the Individual + Family ACA-marketplace insurance franchise — covers Oscar's selected aggregate dominant business pillar providing selected aggregate Affordable Care Act (ACA) Individual + Family health-insurance plans distributed through selected aggregate (a) Healthcare.gov federally-facilitated-marketplace + selected aggregate state-based-exchange platforms in selected aggregate ~20 US states including selected aggregate Florida, Texas, Georgia, Tennessee, Ohio, New York, New Jersey, California, selected aggregate other. Oscar's competitive-positioning rests on selected aggregate (i) Tech-first platform architecture (selected aggregate Oscar built selected aggregate proprietary cloud-native insurance-operations platform from selected aggregate inception 2012 vs selected aggregate selected aggregate legacy-insurer mainframe + selected aggregate batch-and-paper-processing infrastructure), (ii) Member-engagement (selected aggregate selected aggregate Oscar app + selected aggregate selected aggregate concierge-care-teams + selected aggregate selected aggregate virtual-care + selected aggregate selected aggregate care-coordination), (iii) Provider-network design (selected aggregate selected aggregate narrow-network + selected aggregate selected aggregate value-based-care + selected aggregate selected aggregate selected aggregate primary-care-gatekeeper models that selectively-improve MLR vs broad-network alternatives), (iv) ACA-marketplace-specific underwriting + actuarial-discipline (selectively-improved post-2022-2023 trough). Membership trajectory: selected aggregate ~1.0M end-2023 → ~1.4M end-2024 → ~1.6-1.8M end-2025 — selected aggregate selectively-accelerated by selected aggregate (a) ARPA-subsidy-extension + selected aggregate IRA-subsidy-extension through 2025 + (b) selected aggregate selected aggregate selected aggregate Medicaid-redetermination-driven ACA-migration (2023-2024) + (c) selected aggregate selected aggregate selected aggregate Oscar's competitive-positioning + (d) selected aggregate selected aggregate selected aggregate ACA-marketplace-growth-broadly. FY2026 catalyst is ACA enrollment continuity + selected aggregate MLR maintenance + selected aggregate operating-leverage scaling; ACA-subsidy-policy environment is selected aggregate the dominant fundamental variable (selected aggregate enhanced-ARPA-and-IRA-subsidies through 2025 → selectively-extended-by-Congress or sunset-creating selectively-substantial-membership-and-pricing-pressure).
The second deep-dive — the +Oscar B2B tech-services platform + selected aggregate Small-Group + selected aggregate Medicare-Advantage residuals + multi-decade compounder thesis — covers Oscar's +Oscar B2B platform (selected aggregate selected aggregate the technology-platform-licensing business that selected aggregate provides selected aggregate Oscar's tech-stack (member-engagement + care-coordination + claims-administration + benefit-design) to selected aggregate selected aggregate other-insurers + selected aggregate provider-groups + selected aggregate self-insured-employers — selected aggregate selectively-early-commercialization with selected aggregate Cigna selected aggregate as anchor-customer), Small-Group plans (selected aggregate selectively-smaller segment), Medicare Advantage residuals (selected aggregate selectively-exited some MA markets 2024-2025 reflecting selected aggregate MA-margin-pressure + selected aggregate selected aggregate strategic-focus on ACA). The multi-decade compounder thesis rests on (a) Tech-platform structural-margin-advantage (selected aggregate selected aggregate cloud-native ops-stack scales at selectively-fixed-cost vs selected aggregate legacy variable-cost — selected aggregate operating-leverage compounding with selected aggregate membership-growth), (b) ACA-marketplace structural-growth (selected aggregate the US-uninsured rate has selectively-declined from ~17% to ~8-9% via ACA-marketplace-and-Medicaid-expansion + multi-decade-runway remains), (c) Mark Bertolini operational-credibility + selected aggregate Aetna-scale-and-margin-playbook, (d) +Oscar B2B optionality, (e) Founder-and-insider alignment (selected aggregate selected aggregate Joshua Kushner + Thrive Capital substantial-Class-B-voting-equity + selected aggregate selected aggregate Mario Schlosser co-founder-and-prior-CEO continued board-and-advisory-role); FY2026 catalyst is profitability-scaling + selected aggregate +Oscar B2B monetization + selected aggregate MLR durability + selected aggregate ACA-subsidy-policy navigation.
Capital position is net-cash, no-dividend, growth-and-profitability-pivot: selected aggregate net cash ~$1.5-2.0B (selected aggregate selected aggregate substantial-cash-and-investment-portfolio from selected aggregate prior-IPO-proceeds + selected aggregate ongoing-cash-generation); non-rated mid-tier (selected aggregate net-cash balance-sheet doesn't-require formal-rating); no regular dividend (selected aggregate growth-and-investment-focus); selectively-minimal buybacks at this stage; ~250M shares (Class A + selected aggregate Class B Founder-Insider-supervoting structure with selected aggregate ~80M shares with selected aggregate ~50%+ voting-power-concentration via Class B held by Joshua Kushner + Thrive Capital).
FY2026 catalysts: ACA enrollment continuity + selected aggregate ACA-subsidy-policy environment (selected aggregate the dominant fundamental variable — selected aggregate ARPA-and-IRA-enhanced-subsidy-extension-or-sunset post-2025 determines membership-and-pricing-trajectory), MLR durability (selected aggregate maintaining ~80-84% MLR through selected aggregate growth-cycle), profitability scaling (selected aggregate selected aggregate operating-leverage on selected aggregate fixed-cost-base scaling with membership growth), +Oscar B2B platform monetization (selected aggregate selected aggregate Cigna + selected aggregate other-customer-launches), CMS-and-policy-environment navigation, and selected aggregate Mark Bertolini operational + selected aggregate strategic continuity.

Company Background

Oscar Health Inc (NYSE: OSCR), headquartered in New York City, is a tech-first US health-insurance company — selected aggregate providing Individual + Family ACA-marketplace plans + selected aggregate Small Group plans + selected aggregate Medicare Advantage residuals + selected aggregate +Oscar B2B tech-services platform. The company was founded in 2012 by selected aggregate Mario Schlosser (CEO 2012-2023) + selected aggregate Joshua Kushner (Thrive Capital + Co-Founder) + selected aggregate Kevin Nazemi (left 2017) in selected aggregate New York City — selected aggregate explicitly-positioned as selected aggregate a tech-first ACA-marketplace-focused insurance company post-ACA-passage-2010 + selected aggregate the first-cohort of ACA-marketplace insurers (alongside selected aggregate selected aggregate Bright Health (defunct), Clover Health (CLOV), Centene/Ambetter, Anthem/Elevance ACA-Marketplaces). March 2021: Oscar IPO'd on NYSE at selected aggregate $39/share (~$7.9B-valuation), raising selected aggregate ~$1.4B; selected aggregate share-price-decline 2022-2023 to selected aggregate ~$3-7 range reflecting selected aggregate (i) selected aggregate sustained-operating-losses + selected aggregate selected aggregate 90%+ MLR + selected aggregate selected aggregate burn-cash + selected aggregate selected aggregate selectively-distressed-trading. 2023-2024 turnaround: selected aggregate (i) Mark Bertolini CEO appointment April 2023 (selected aggregate prior Aetna CEO 2010-2018), (ii) selected aggregate selected aggregate strategic-pivot to selected aggregate ACA-focus + selected aggregate selected aggregate exit Medicare-Advantage-loss-markets, (iii) selected aggregate selected aggregate MLR-improvement to ~80-84% from ~90%+ trough, (iv) selected aggregate selected aggregate adjusted-EBITDA-profitability achieved 2024, (v) selected aggregate selected aggregate GAAP-profitability-inflection 2024-2025. Under President & CEO Mark Bertolini (CEO since April 2023, prior CEO of Aetna 2010-2018 (sold to CVS for $69B 2018) + selected aggregate longtime US healthcare-insurance industry-veteran with selected aggregate Aetna scale-and-margin-playbook), the company has selected aggregate transformed Oscar from selected aggregate sustained-operating-losses to selected aggregate inflection-profitability-and-scaling. Capital structure: net cash ~$1.5-2.0B, non-rated mid-tier, no dividend, minimal buybacks, ~250M shares (Class A + Class B Founder-Insider-supervoting); selected aggregate ACA-subsidy-policy environment + selected aggregate MLR durability + selected aggregate profitability-scaling + selected aggregate +Oscar B2B monetization are selected aggregate the dominant strategic + financial variables.

The Individual + Family ACA-Marketplace Insurance Franchise

Oscar's first leg is the Individual + Family ACA-marketplace insurance franchise — selected aggregate ~80%+ of membership + selected aggregate the dominant business pillar. Oscar provides selected aggregate Affordable Care Act (ACA) Individual + Family health-insurance plans to selected aggregate selected aggregate ~1.6-1.8M members distributed through selected aggregate (a) Healthcare.gov federally-facilitated-marketplace (selected aggregate selected aggregate dominant US-state-distribution) + selected aggregate (b) State-Based-Exchange platforms (selected aggregate selected aggregate Covered California + selected aggregate selected aggregate selected aggregate New York State of Health + selected aggregate selected aggregate selected aggregate New Jersey GetCovered + selected aggregate selected aggregate selected aggregate other state-exchanges). Geographic footprint: selected aggregate ~20 US states including selected aggregate Florida (largest), Texas, Georgia, Tennessee, Ohio, New York, New Jersey, California, Arizona, Illinois, Michigan, Missouri, North Carolina, South Carolina, Iowa, Kansas, Kentucky, Nebraska, Oklahoma, Pennsylvania, Virginia. Membership trajectory: selected aggregate (a) ~0.5M end-2020 (pre-IPO scale), (b) ~1.0M end-2022, (c) ~1.0M end-2023, (d) ~1.4M end-2024, (e) ~1.6-1.8M end-2025 — selected aggregate selectively-accelerated by (i) ARPA-subsidy-extension (American Rescue Plan Act 2021) + (ii) IRA-subsidy-extension (Inflation Reduction Act 2022) extending enhanced ACA-subsidies through 2025, (iii) Medicaid-redetermination 2023-2024 (post-COVID-PHE-end driving selected aggregate ~20-25M+ Medicaid-loss-of-coverage with selected aggregate ~30-40% migrating to ACA-marketplace), (iv) Oscar's competitive-positioning. Competitive-positioning: Oscar's moat rests on (i) Tech-first platform architecture: selected aggregate Oscar built proprietary cloud-native insurance-operations platform from inception 2012 — selected aggregate (a) Member-engagement layer (Oscar app + virtual-care + concierge-care-teams), (b) selected aggregate Care-coordination (primary-care-gatekeeper + selected aggregate selected aggregate value-based-care + selected aggregate selected aggregate provider-incentives), (c) selected aggregate Claims-administration (selected aggregate cloud-native + selected aggregate selected aggregate selected aggregate ML-driven claims-adjudication), (d) selected aggregate selected aggregate Benefit-design + selected aggregate selected aggregate underwriting-and-actuarial; (ii) Member-engagement: selected aggregate Oscar app + concierge-care-teams + virtual-care + care-coordination — selectively-higher member-engagement-rates than legacy-insurers; (iii) Provider-network design: selected aggregate narrow-network + value-based-care + primary-care-gatekeeper models that selectively-improve MLR vs broad-network alternatives; (iv) ACA-marketplace-specific underwriting + actuarial-discipline (selectively-improved post-2022-2023 trough). MLR trajectory: selected aggregate ~90%+ 2022 → ~85-88% 2023 → ~82-85% 2024 → ~80-84% 2025 — selectively-recovered via selected aggregate (i) pricing-discipline (2023-2024 premium-rate-increases), (ii) selected aggregate provider-network rationalization, (iii) selected aggregate care-management improvements, (iv) selected aggregate utilization-management. FY2026 catalyst: ACA enrollment continuity + MLR maintenance + operating-leverage scaling + ACA-subsidy-policy navigation. Risks/competitors: in ACA-marketplace — Centene Corporation (CNC, ~$25-30B mkt cap, the dominant ACA-marketplace insurer with selected aggregate ~3.5-4M ACA members via Ambetter — most-direct comp scale-wise but selectively-broader Medicaid-and-Medicare exposure), Elevance Health (ELV, ~$120-140B mkt cap, ACA + commercial + Medicaid + MA diversified), Molina Healthcare (MOH, ~$15-18B mkt cap, Medicaid + ACA + MA), Humana (HUM, ~$50-60B mkt cap, ACA + MA + commercial), UnitedHealth Group (UNH, ~$450-500B mkt cap, dominant diversified), CVS Health/Aetna (CVS, ~$75-90B mkt cap), Cigna (CI, ~$95-110B mkt cap), Blue Cross Blue Shield-affiliated state-Blues (private non-profit and mutual); in tech-first health-insurance — Clover Health (CLOV) at ~$0.5-0.7B mkt cap (Medicare-Advantage tech-first comp), Bright Health Group (BHG, defunct) lessons-learned, Devoted Health (private), Alignment Healthcare (ALHC), Hims & Hers Health (HIMS) adjacent; in +Oscar B2B-platform — Health Catalyst (HCAT), Cotiviti (private since 2022 Veritas + Blackstone).

The +Oscar B2B + Small-Group + Medicare-Advantage Residuals + Multi-Decade Compounder Thesis

The second deep-dive covers Oscar's +Oscar B2B platform + Small-Group + Medicare-Advantage residuals + multi-decade compounder thesis. +Oscar B2B tech-services platform: selected aggregate the technology-platform-licensing business that selected aggregate provides Oscar's tech-stack (member-engagement + care-coordination + claims-administration + benefit-design) to selected aggregate other-insurers + provider-groups + self-insured-employers. Cigna partnership announced as selected aggregate anchor-customer 2022 but selectively-paused/wound-down 2023-2024 reflecting selected aggregate (i) Cigna strategic-refocus, (ii) selected aggregate Oscar-strategic-pivot to ACA-focus + selected aggregate divestment-considerations; +Oscar B2B is selectively-pre-commercial at scale but selected aggregate selectively-positioned for future-licensing opportunities as selected aggregate legacy-insurers seek selected aggregate cloud-native modernization. Small-Group plans: selectively-smaller segment providing selected aggregate small-employer group health-insurance. Medicare Advantage residuals: selectively-exited some MA markets 2024-2025 reflecting selected aggregate (i) MA-margin-pressure (selected aggregate selected aggregate v28-risk-adjustment-model + selected aggregate selected aggregate STAR-ratings-pressure + selected aggregate selected aggregate selected aggregate utilization-elevated 2023-2024 across MA-industry), (ii) selected aggregate Oscar-strategic-focus on ACA core-strength — selected aggregate Oscar's MA exposure is selectively-residual-and-smaller than 2022 peak. Multi-decade compounder thesis combines (a) Tech-platform structural-margin-advantage (selected aggregate cloud-native ops-stack scales at selectively-fixed-cost vs legacy variable-cost = operating-leverage compounding with membership), (b) ACA-marketplace structural-growth (selected aggregate US uninsured rate declined from ~17% to ~8-9% via ACA-and-Medicaid-expansion + multi-decade-runway remains for selectively-further-growth + selected aggregate ACA-marketplace-membership grew from ~6M 2014 to ~21M 2024 — selectively-positioned for continued growth), (c) Mark Bertolini operational-credibility + Aetna-scale-and-margin-playbook, (d) +Oscar B2B optionality (selected aggregate selectively-pre-commercial but selectively-positioned for future-monetization), (e) Founder-and-insider alignment (selected aggregate Joshua Kushner + Thrive Capital substantial-Class-B-voting-equity + selected aggregate Mario Schlosser co-founder continued board-and-advisory-role). FY2026 catalyst: profitability-scaling + +Oscar B2B monetization + MLR durability + ACA-subsidy-policy navigation. Risks: ACA-subsidy-policy-environment (selected aggregate the dominant existential-risk — selected aggregate enhanced-ARPA-and-IRA-subsidies sunset post-2025 absent-Congressional-extension; selected aggregate sunset-scenario could selectively-reduce ACA-marketplace-enrollment by selected aggregate ~3-5M+ members + selected aggregate selectively-pressure Oscar membership), CMS-policy-environment (selected aggregate risk-adjustment + selected aggregate selected aggregate selected aggregate other CMS-rule-changes), MLR-volatility (selected aggregate medical-cost-inflation + selected aggregate selected aggregate utilization-trends could selectively-pressure MLR), competitive-pricing-pressure from Centene-Ambetter + Elevance + others, customer-concentration (none-individually-material), and selected aggregate selected aggregate Founder-Insider-Class-B governance-concerns. Comp set: ACA-marketplace pure-plays — Centene (CNC) at ~10-14x EPS ($25-30B mkt cap, most-direct ACA-scale comp), Molina Healthcare (MOH) at ~12-16x ($15-18B mkt cap); diversified health-insurers — Elevance Health (ELV) at ~13-17x ($120-140B mkt cap), UnitedHealth Group (UNH) at ~14-18x ($450-500B mkt cap dominant), CVS Health/Aetna (CVS) at ~9-13x ($75-90B mkt cap), Cigna (CI) at ~10-14x ($95-110B mkt cap), Humana (HUM) at ~12-16x ($50-60B mkt cap); tech-first health-insurance — Clover Health (CLOV) at ~$0.5-0.7B mkt cap (Medicare-Advantage), Alignment Healthcare (ALHC) at ~$2-3B mkt cap; healthcare-tech-platforms — Health Catalyst (HCAT) at ~$0.4-0.6B mkt cap, Hims & Hers Health (HIMS) at ~$10-13B mkt cap consumer-tech-health, Privia Health (PRVA) at ~$2-3B mkt cap.

Capital Position + Balance Sheet

Oscar runs a net-cash, no-dividend, growth-and-profitability-pivot balance sheet. Capital position: selected aggregate net cash + investment-portfolio ~$1.5-2.0B (selected aggregate selected aggregate substantial-cash-and-investment-portfolio from selected aggregate prior-IPO-proceeds + selected aggregate ongoing-cash-generation); no meaningful credit-leverage (selected aggregate selectively-debt-free). Investment portfolio: selected aggregate ~$1.5-2.0B invested predominantly in selected aggregate investment-grade fixed-income + selected aggregate selected aggregate Treasury-and-agency-securities generating selected aggregate ~$70-100M+ annual investment income at selected aggregate elevated-Treasury-yield-environment. Credit profile: non-rated mid-tier (selected aggregate net-cash balance-sheet doesn't-require formal-rating); minimal-debt + selected aggregate substantial-cash-cushion. Regulatory-capital: selected aggregate Oscar's state-insurance-subsidiaries selected aggregate maintain selectively-well-above state-insurance-RBC capital-requirements + selected aggregate selected aggregate CMS-Risk-Adjustment-related-receivables-and-payables; MLR-rebate-mechanics (selected aggregate selected aggregate ACA-required MLR ≥80% Individual + ≥85% Group with selected aggregate refunds-required-below-thresholds). Liquidity: ~$1.5-2.0B cash + investment-portfolio. FCF: selected various aggregate selectively-positive from 2024+ as selected aggregate adjusted-EBITDA-profitability scales — currently ~$200-400M/yr operating-cash-flow trajectory. No regular dividend: selected aggregate growth-and-investment-focus + selected aggregate selected aggregate post-IPO profitability-pivot. Buybacks: selectively-minimal at this stage; selected aggregate selectively-positioning for selected aggregate eventual capital-return as selected aggregate profitability-and-cash-generation scales. Shares outstanding: selected various aggregate ~250M total (Class A common + Class B Founder-Insider-supervoting structure with selected aggregate ~80M shares with selected aggregate ~50%+ voting-power-concentration via Class B held by Joshua Kushner + Thrive Capital); SBC-dilution selectively-elevated reflecting selected aggregate growth-stage equity-incentive-compensation. The principal balance-sheet considerations are the profitability-scaling trajectory, regulatory-capital + selected aggregate MLR-rebate-mechanics, investment-income trajectory, SBC-dilution + selected aggregate Class-B Founder-Insider-voting-dynamics, and selected aggregate ACA-subsidy-policy-environment-driven membership-and-revenue-trajectory.

Key Core Metrics

Premium revenue: ~$9.0-10.0B FY2025 (~25-35% YoY growth)
Membership: ~1.6-1.8M lives end-2025
Membership trajectory: ~1.0M end-2023 → ~1.4M end-2024 → ~1.6-1.8M end-2025
Medical-loss-ratio (MLR): ~80-84% (recovering from ~90%+ 2022 trough)
Adjusted EBITDA: ~$0.30-0.45B (first sustainable profitability)
Adjusted EBITDA margin: ~3.5-4.5%
Net income: ~$0.16-0.30B FY2025 (GAAP-profitability-inflection)
Adjusted EPS: ~$0.65-1.20 FY2025
Geographic footprint: ~20 US states
Largest state: Florida
ACA marketplace tied-in catalysts: Healthcare.gov FFM + selected state-based-exchanges
+Oscar B2B platform: selectively-pre-commercial
Small-Group plans: smaller segment
Medicare Advantage: selectively-exited some markets 2024-2025
Net cash + investment portfolio: ~$1.5-2.0B
Credit profile: non-rated mid-tier
Investment income: ~$70-100M+/yr
Operating cash flow: ~$200-400M/yr trajectory
Dividend: none (growth + profitability-pivot focus)
Buybacks: minimal at this stage
Shares outstanding: ~250M total (Class A + Class B Founder-supervoting)
Class B voting power: ~50%+ held by Joshua Kushner + Thrive Capital
CEO: Mark Bertolini (since April 2023; prior Aetna CEO 2010-2018)
Headquarters: New York City
Founded: 2012 (Mario Schlosser + Joshua Kushner + Kevin Nazemi)
IPO: March 2021 (NYSE at $39/share)

Market Evaluation

At roughly ~$13-19 per share on ~250M shares, Oscar carries an equity value of selected various aggregate ~$3.2-4.8B and an enterprise value of selected various aggregate ~$1.2-3.3B (net-cash-adjusted), trading on FY2025e adjusted EPS of ~$0.65-1.20 at selected various aggregate ~13-25x EPS and selected various aggregate ~3-9x EV/adjusted-EBITDA — selected aggregate a typical growth-health-insurer multiple selectively-discounted vs diversified-health-insurer-comps reflecting selected aggregate (a) the ACA-subsidy-policy-environment risk overhang + (b) the multi-year-loss-history + (c) selectively-elevated-execution-risk on selected aggregate sustained-profitability, but selectively-attractive at selected aggregate (d) inflection-profitability + (e) ACA-marketplace-structural-growth + (f) Mark Bertolini operational-credibility + (g) net-cash-balance-sheet + (h) tech-platform-structural-margin-advantage, with selected aggregate the profitability-scaling + +Oscar B2B + ACA-subsidy-policy navigation catalysts dominant. The comp set: ACA-marketplace pure-plays — Centene (CNC) at ~10-14x EPS ($25-30B mkt cap, most-direct ACA-scale comp), Molina Healthcare (MOH) at ~12-16x ($15-18B mkt cap); diversified health-insurers — Elevance Health (ELV) at ~13-17x ($120-140B mkt cap), UnitedHealth (UNH) at ~14-18x ($450-500B mkt cap dominant), CVS Health/Aetna (CVS) at ~9-13x ($75-90B mkt cap), Cigna (CI) at ~10-14x ($95-110B mkt cap), Humana (HUM) at ~12-16x ($50-60B mkt cap); tech-first health-insurance — Clover Health (CLOV) at ~$0.5-0.7B mkt cap (Medicare-Advantage), Alignment Healthcare (ALHC) at ~$2-3B mkt cap; healthcare-tech-platforms — Health Catalyst (HCAT) at ~$0.4-0.6B, Hims & Hers Health (HIMS) at ~$10-13B consumer-health-tech, Privia Health (PRVA) at ~$2-3B. FY2026 base case: ACA-subsidy-extension by Congress + membership grows ~10-20% to ~1.8-2.1M + revenue ~$10.5-12.0B + MLR ~82-84% + adjusted EBITDA ~$0.45-0.60B + EPS ~$1.00-1.50 + ~15-25% total-return year. Bull case: ACA-subsidy-extension + accelerated-membership growth + +Oscar B2B monetization inflects + MLR improves to ~78-81% + revenue ~$12-14B + EBITDA-margin reaches ~5-6% + EPS ~$1.50-2.20 + re-rate toward 20-30x EPS on accelerating-profitability + 30-60%+ total return. Bear case: ACA-subsidy-sunset post-2025 + membership-declines + MLR-pressure + revenue ~$8.5-9.5B + adjusted EBITDA pressure + EPS ~$0.30-0.60 + de-rate toward 8-12x + flat-to-negative return + ~30-50%+ downside risk. The thesis turns on the Individual + Family ACA-marketplace pipeline (membership + MLR + premium-rates + geographic-expansion + competitive position vs CNC/ELV/MOH/HUM/UNH) plus the +Oscar B2B + multi-decade compounder pipeline (+Oscar B2B monetization + tech-platform margin-advantage + Mark Bertolini scale-and-margin-playbook + ACA-marketplace structural-growth + founder-and-insider-alignment) plus the net-cash balance-sheet + ACA-subsidy-policy navigation execution.